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Abstract
Urinary tract infection (UTI) is one of the most common infections in both the commu-
nity as well in hospital settings. It is mostly caused by Gram-negative bacteria (GNBs). 
Over the past two decades, GNBs have developed complex mechanisms of resistance 
against most of the potent antibiotics. This has been a global challenge which has been 
identified by the World Health Organization as “one of the greatest threats to human 
health.” This crisis is mostly attributed to the overuse and misuse of these medica-
tions, as well as lack of new drug antimicrobials by the pharmaceutical industry. This 
resulted in prolonged hospital stay, marked increase in the cost as well as increase in 
morbidity and mortality. Furthermore, it increases the risks and complications of uro-
logical procedures. In this chapter, we review the management of the most common 
and challenging group of resistant Gram-negative organisms, the extended-spectrum 
β-lactamases producing organisms (ESBL) and the carbapenem-resistant organisms 
(CRE/CRP). The latter group includes carbapenem-resistant Enterobacteriaceae (CRE), as 
well as Pseudomonas aeruginosa carbapenemases (CRP). When treating these infections, 
clinicians have few effective antimicrobials options. A critical step in managing these 
organisms is the early recognition and appropriate empiric therapy. Both showed mor-
bidity and mortality benefits.
Keywords: urinary tract infection (UTI), Gram-negative bacteria (GNBs), complicated 
urinary tract infections (CUTIs), extended-spectrum β-lactamases producing organisms 
(ESBL), carbapenem-resistant organisms (CRE/CRP), carbapenems,  
ceftazidime-avibactam, colistin, fosfomycin, Enterobacteriaceae
1. Introduction
Urinary tract infection is the second most common infectious presentation in community as 
well as in hospital settings. It has been estimated that 150 million people are diagnosed with 
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UTI each year worldwide [1]. It is mostly caused by GNBs. Over the past two decades, GNBs 
have developed complex mechanisms of resistance against most of the potent antibiotics. This 
has been a global challenge which has been identified by the World Health Organization as 
“one of the greatest threats to human health” [2]. This crisis is mostly man-made as it is attrib-
uted to the overuse and misuse of these medications, as well as a lack of new drug develop-
ment by the pharmaceutical industry seeking better profitable agents.
This resulted in prolonged hospital stay, marked increases in the cost as well as increase in 
morbidity and mortality [3–6]. Furthermore, bloodstream infections associated with severe 
complicated urinary tract infections (CUTIs) are associated with high mortality rates of 
20–50% among critically ill patients. Many urological procedures are complicated with such 
infectious manse, frustrating the surgeons and the patients [7].
Multiple mechanisms that enable the organism to become resistant include enzymatic trans-
formation, modification of site of action, active efflux from the cell interior and, the prevention 
of entry of the molecules into the cell [8].
There are different confusing terminologies in addressing this process. An international panel 
of experts developed the following definitions: multidrug-resistant (MDROs) means acquir-
ing nonsusceptibility to at least one agent in three or more antimicrobial categories, exten-
sively drug-resistant (XDR) is nonsusceptible to at least one agent in all, but two or fewer 
antimicrobial categories, and pan-drug-resistant (PDR) isolates are nonsusceptible to any of 
the available antimicrobial classes [1, 9, 10].
The term “ESKAPE” was one of the former descriptions of pathogens that cause the majority 
of hospital infections while effectively “escaping” the effects of available therapeutics. Other 
terms include “SPICE organisms” which include many Gram-negative bacteria that have 
inducible, chromosomal AmpC β-lactamase genes. The resistance to antibiotics may not be 
detectable initially, but appears after a period of exposure to β-lactam antibiotics (during 
therapy or after).
We are focusing in this review on the most common and challenging groups of resistant 
Gram-negative organisms, the ESBL, and the CRE, as well as CRP. The other highly resistant 
organism, such as Acinetobacter baumannii, less frequently causes urinary tract infection and 
its therapy is even more complicated [11–13].
When treating these infections, clinicians have a few effective antimicrobials to choose from 
and many are associated with significant adverse effects. A critical step in managing these 
organisms is the early recognition and appropriate empiric therapy. Both showed morbidity 
and mortality benefits. In this chapter we will review the available data on managing UTIs 
caused by ESBL and the CRE/CRP.
2. Materials and methods
The purpose of this chapter is to review the available data on managing UTIs caused 
by resistant Gram-negative bacteria. Clinical trials and review articles (in English) were 
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identified from a Medline search (2000–2017), in addition to laboratory data and abstracts 
from international Conferences.
2.1. Definition: ESBL organisms
The term ESBL was originally applied to plasmid-encoded β-lactamases that are capable of 
inactivating extended-spectrum cephalosporins and are inhibited by β-lactamase inhibitors, 
such as clavulanic acid. Enterobacteriaceae, primarily Escherichia coli and Klebsiella pneumoniae, 
are among the most frequently producing bacteria [9].
ESBLs are plasmid-encoded or chromosomally encoded β-lactamases with broad activity 
against penicillins and cephalosporins. They are a diverse group of bacterial enzymes that break 
down and inactivate most β-lactam antibiotics. They are inhibited by the available β-lactamase 
inhibitors (clavulanic acid, sulbactam, avibactam, and tazobactam) and do not affect cephamy-
cins (e.g., cefoxitin and cefotetan) or carbapenems. β-Lactamases are divided into A, B, C, and 
D classes according to their amino acid sequence homology (Ambler classification) [14].
These bacteria are usually multi-resistant, as they are frequently capable of resisting other 
antibiotics, such as the aminoglycosides, tetracyclines, and trimethoprim/sulfamethoxazole 
though other mechanisms, leaving few treatment options [3]. As these resistant genes are 
plasmid-mediated, they can be easily disseminated to other bacterial species [15–17]. UTIs 
caused by these organisms are seen at alarming rates in both hospital infection and in the 
community settings [15, 18, 19].
Although 95–100% ESBL organisms are still considered sensitive to carbapenems, rapid emer-
gence of carbapenem resistance has been documented globally, and was linked to the over 
usage of these agents [20].
2.2. Epidemiology
Surveillance in Asia, Latin America, and Europe revealed dramatically increasing resistance 
to cephalosporins among E. coli and Klebsiella spp. [21]. In a large study in Turkey (SMART), 
the rate of ESBL in E. coli isolated from urine samples was high (50% hospital isolates and 38% 
community acquired isolates) [22, 23].
In one study, 21,414 positive urine cultures were collected from a University hospital in the 
UK. There were 1420 ESBL-positive specimens. There were a 44% increase, from 4.6 to 6.6%, 
of the ESBL-positive organisms over 2 years.
Multidrug resistance were detected in 75% of ESBL + Klebsiella spp. against >6 antibiotic 
classes [24].
In the CHINET surveillance system data from 2005 to 2014, ESBL production among E. coli 
isolates was between 51.7 and 55.8% [25].
The spreading of such isolates in the community is well documented, so containment of this 
type of bacterial infection will be real challenging [23]. There were many outbreaks caused by 
these organisms all over the globe with high morbidity and mortalities [17].
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2.3. Risk factors
Many studies have implicated broad-spectrum cephalosporins as the major class associated 
with ESBL production; others considered fluoroquinolone and β-lactam-β-lactamase inhibi-
tor combinations, as the main risk factors for ESBL infections [26]. Other risk factors include 
nursing home residence, diabetes, recurrent UTIs, male gender, prolonged hospitalization, 
intensive care admission, and urinary catheterization [19, 24, 27–29].
Prospective cohort study of 225 healthy German volunteers traveling to 53 different countries 
(mostly in Asia, Africa, and S. America) evaluated the risk of ESBL colonization. Stool samples 
were collected before and after traveling. The isolates were examined phenotypically and 
by PCR amplification sequencing. Among 191 participants that were ESBL-negative before 
travel, 30% were colonized by ESBL-producing E. coli after returning home [29, 30].
The use of antibiotics in farm animals as growth promoters is linked to this global disaster. 
In a recent study from India, 18 poultry farms were surveyed, 16 of them reported using 
antimicrobials for growth promotion. There were 1556 E. coli isolates, collected and tested. 
The prevalence of ESBL-positive strains in broiler farms was 87% [31]. Multiple studies have 
shown the benefit of early identifications of this organism, to offer the appropriate empiric 
therapy. A simple predicting score for early recognition was recently published. Four risk fac-
tors were identified; each was given a score of one. Scores above 2 had a sensitivity of (84%) 
and a specificity of (92%). These variables include recent antimicrobial use (OR, 15.29), recent 
invasive procedures (OR, 12.33), nursing home residents (OR, 27.77), and frequent emergency 
department visits (OR, 9.98) [32].
2.4. Mechanism of resistance
The most common mechanisms include enzymatic inactivation, target modification, reduced 
permeability, and active efflux. Antibiotic resistance can be intrinsic to specific microorgan-
isms, which can be explained by their inherent characteristics. Point mutations on β-lactamase 
genes are responsible for emergence of ESBLs. These new genes could be transmitted through 
small mobile genetic element DNA (plasmid, transposons) to other bacteria from same or 
other species [5, 8].
A more distinct type of ESBL including CTX-M-type, AmpC, and carbapenemase, can confer 
phenotypic resistance that widens the resistance abilities against more antibiotics than the 
classical isolates [33].
2.5. Detection
These organisms are capable of resisting most of the third-generation cephalosporins but they 
are inhibited by clavulanate. This is the basis of detecting these organisms using routine labo-
ratory tests such as double disk diffusion test or E-test. The size of zone of inhibition around 
one or more of the β-lactam-containing discs toward the clavulanic acid-containing disc is 
indicative of some ESBL producers [34, 35].
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The detection of specific genes by PCR and sequencing are commonly used for final confir-
mation of ESBL producers. A commercially available multiplex real-time PCR can detect the 
predominant class A β-lactamase genes blaCTX-M, blaSHV, blaTEM, and CIT-type AmpCs with high sensitivity and it is much faster than routine cultures [36].
2.6. Carbapenem resistant organisms
The carbapenems are the most potent agents with wide spectra of coverage. They are the 
most dependent agents in critical infectious syndromes. However, resistance to these agents 
has increasingly been reported worldwide, rendering them increasingly ineffective. These 
organisms are also capable of resisting other classes of antibiotics (aminoglycosides, fluo-
roquinolone, and co-trimoxazole), due to the frequent coexistence of other resistance genes 
on the same mobile genetic elements, rendering them superbugs. The most recent example 
is the emergence of colistin resistant genes in isolates which are already resistant to the 
carbapenems.
K. pneumoniae carbapenemase (KPC-class A) was the first CRE enzyme to be reported in 
2001. New Delhi metallo-β-lactamase (NDM-class B) is one of the most recently reported 
metallo-enzymes. It has spread widely in the Indian sub-continent and now worldwide. 
The oxacillinase-48 type (OXA-48-class C) has been identified mostly in Mediterranean 
and southern European countries. Other mechanisms of resistance include efflux pump 
over activity (pumping the antibiotics out of the bacterial cell), hyper production of AmpC 
β-lactamase in the already highly resistant ESBL organisms, and changes in porin perme-
ability [8].
Infections with such resistant isolates resulted in high morbidity, prolonged hospital stay, 
and mortality [37, 38]. In a pooled analysis of the 9 studies (985 patients), the mortal-
ity rate was higher among CRE-infected than carbapenem susceptible Enterobacteriaceae-
infected patients (RR 2.05, 95% CI 1.56–2.69). The authors calculated 26–44% of deaths 
from 7 studies attributable to carbapenem resistance [39]. The rate was even higher (61%) 
in patients infected with KPC-expressing K. pneumoniae who received initially ineffective 
therapy [40].
2.7. Epidemiology
A multicenter observational study in 11 hospitals from 7 Latin American countries that 
included 255 patients with bacteremia was reported. Twenty-three percent of the isolates 
were CRE/CRP [38].
According to the latest data collected by the European Antimicrobial Resistance Surveillance 
Network (EARS-Net), the rate of CRE rose from 6.2% in 2012 to 8.1% in 2015 [41].
CRE are more prevalent in Italy and Greece. In an active surveillance study, rectal swabs (and 
clinical samples) were collected from 15,104 hospitalized patients (over 2 years). K. pneumoniae 
CRE was detected in 496 consecutive non-replicated samples [42].
Resistant Gram-Negative Urinary Tract Bacterial Infections
http://dx.doi.org/10.5772/intechopen.71872
89
In a Greek study, 3449 K. pneumoniae isolates were recovered over 10 years. Among them, 
1668 (48%) were CRE-producing. Sixteen percent of the isolates were resistant to colistin [43].
2.8. Detection
These include antimicrobial susceptibility testing, modified Hodge testing, and inhibitor-
based testing. In 2015, the CDC-CRE surveillance definition was revised to one of two criteria: 
(1) resistance to any carbapenem according to current CLSI breakpoints (MIC ≥ 2 for ertape-
nem or ≥4 for doripenem, meropenem, or imipenem) or (2) demonstration of carbapenemase 
production. Several phenotypic assays are available commercially detecting carbapenemase 
production from bacterial culture within hours. The Carba NP test has high sensitivity and 
specificity that can differentiate between class A, B, and C CRE. In one study, its specificity 
and sensitivity were almost 96% [44].
There are many commercially available PCR-based testing for early recognition and 
confirmation.
2.9. Therapy of urinary tract infections caused by MDROs
2.9.1. ESBL-producing β-lactamases
In general and for serious life threatening infections, the carbapenems are the drugs of choice 
for infections caused by these organisms [12, 35]. However, the surge in using the carbapen-
ems, resulted in the evolution of CRE/CRP, so there were multiple recent trials evaluating, 
carbapenem-sparing are regimens, mostly for less severe infections [12, 45–48].
2.9.2. CRE/CRP
In general, there is no clear consensus on managing these organisms. The available data are 
drawn from expert opinion or from small trials. There are few controlled trials that deter-
mined the best therapeutic so far [49, 50].
In the following sections, we will review the available data on different classes of antibiotics 
that have been used in managing ESBL, and then if applicable, will discuss their roles in treat-
ing CRE/CRP.
2.9.2.1. Carbapenems
They have a broad spectrum of antimicrobial activity more than any other classes of anti-
microbials, and are potent bactericidal (ertapenem lakes anti-pseudomonas activities) 
[51–54].
In multiple non-randomized studies that included large number of patients with bacteremia, 
sepsis, and other serious infections, they showed high cure-improvement rates with great 
safety profile [54, 55].
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Studies of the pharmacokinetic/pharmacodynamics data also showed superiority of this class 
of antibiotic in achieving the proper concentration above the bacterial minimal inhibitory 
concentrations (MICs) [56].
In vitro activities against many ESBL isolates are well documented against large collections of 
ESBL producing Enterobacteriaceae and P. aeruginosa isolates [57].
For treating CRE/CRP, limited data on combination regimens involving carbapenems (if MICs 
≥ 8  mg/L) adding colistin or high-dose tigecycline or aminoglycoside or even triple combina-
tions, seem to confer decent therapeutic advantage over monotherapy. For organisms with 
higher MIC, a combination of two or even three antibiotics may be needed.
In a recent meta-analysis of 22 studies of using, the most common regimen, carbapenems plus 
colistin or polymyxin had mortality advantages [38].
On the other hand, a retrospective study of 436 patients were recruited in the INCREMENT 
study-cohort (26 tertiary hospitals from 10 countries). The main outcome variable was 
30 day all-cause mortality in patients with CRE/CRP bloodstream infection. Overall mortal-
ity was not different between those receiving combination therapy and monotherapy (35% 
vs. 41%) [58].
Synergy is another potential benefit arising from the use of antibiotic combinations.
Tigecycline with colistin, colistin with a carbapenem, fosfomycin with a carbapenem, fos-
fomycin with an aminoglycoside, and a carbapenem with an aminoglycoside have been 
reported as antibiotic combinations effectively administered to series of patients infected with 
carbapenemase-producing Enterobacteriaceae [4].
Efforts have been exerted to limit the usage of their precious agents by using alternative regi-
mens whenever [46].
2.9.2.2. Piperacillin-tazobactam (PTZ)
PTZ is a broad-spectrum drug combination used in serious infections. However, the extensive 
usage of this agent accelerated the emergence of resistance [48, 59].
Some ESBL E. coli producers’ isolates might have high in vitro susceptibility to PTZ; however, 
its clinical utility in serious UTIs, especially when associated with bacteremia, has been con-
troversial. In a prospective, randomized, open-label comparison of the therapeutic efficacy 
of (PTZ), cefepime, and ertapenem in nosocomial UTIs with ESBL producers, 66 participants 
were evenly randomized to the PTZ and ertapenem treatment groups (cefepime arm was 
eliminated because of high treatment failure rate). The clinical and microbiological responses 
to both antibiotics were similar around 94% [60].
Similar non-inferiority of PTZ to carbapenems was shown in a retrospective analysis of blood-
stream infection by an ESBL-producing organism, if susceptible in vitro [61].
In a post hoc analysis of patients with bloodstream infections due to ESBL producing isolates 
from 6 published prospective cohorts, the effect of amoxicillin-clavulanic acid, PTZ, and 
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carbapenems were compared. The mortality rates at day 30 were much higher with the first 
2 antibiotics than with carbapenems [62].
In a retrospective observational study, 331 patients with ESBL bacteremias were evaluated. 
Empiric therapy with PTZ was used in 48% while 52% received carbapenems. The adjusted 
risk of death (14-day mortality) was 1.92 times higher for patients receiving empiric PTZ com-
pared with carbapenem therapy (95% confidence interval, 1.07–3.45) [63].
In an editorial that tried to explain these controversial results, the authors mentioned various 
variables including the inoculum of the bacteria in the bloodstream, the sources of bacteremia 
(less fatal if from UTIs than central line infections), selection bias inherent to observational 
studies, and the presence of different genetic and virulence of the included bacteria [35].
A large recent multicenter randomized controlled open-label non-inferiority trial, MERINO 
trial, comparing meropenem (standard arm) against PTZ in adult patients with bacteremia 
caused by E. coli or Klebsiella spp., is ongoing, and hopefully, it will provide better answer to 
these conflicting data [61].
2.9.2.3. Cephalosporins
Cephalosporins have been less effective than comparative regimens in treating severe/seri-
ous infections with ESBL-producing bacteria. They are rapidly hydrolyzed by many ESBLs 
stains [60].
In many clinical studies, it was associated with a trend toward clinical and microbiological 
failure, as well as a trend of increased mortality [64, 65].
Despite their in vitro activities, there are reports of mutations and/or acquiring plasmids 
encoding AmpC-resistant genes during therapy with these agents. Others concerns about this 
agent failure include the decreased activity with high bacterial load (inoculum effect) and 
the failure to meet necessary pharmacodynamics targets due to inadequate dosing and/or 
interval schedules [50].
The most studied agent in this class is the cefepime. In the above-mentioned recent prospec-
tive, randomized, open-label that compared (PTZ), cefepime, and ertapenem in nosocomial 
UTIs, the microbiological and therapeutic efficacies of cefepime in febrile nosocomial urinary 
tract infection with ESBL E. coli were much less than the other competitors at 33% [60].
Data is more clear in patients with serious infections associated with ESBL-producing 
organisms’ bloodstream infections. In a recent study, the mortality risk was 2.87 times 
higher for patients receiving cefepime compared with carbapenems (95% confidence inter-
val (0.88–9.41) [66].
Another retrospective study included adult patients with BSI due to ESBL-producing K. pneu-
moniae or E. coli. In multivariate analysis, using cefepime as empirical therapy was associated 
with a trend toward an increased mortality risk, while empirical carbapenem therapy was 
associated with a trend toward decreased mortality [65].
Urinary Tract Infection - The Result of the Strength of the Pathogen, or the Weakness of the Host92
There is few data from limited studies (with small number of participants) that showed 
cefepime is effective if used against in vitro susceptible ESBL-producing Enterobacteriaceae 
and as a de-escalation therapy in patients with uncomplicated UTIs [53, 67].
There are less robust data for the efficacy of other cephalosporins, cefmetazole (a cephamycins), 
in treating patients with extended-spectrum β-lactamase producing [68].
2.9.2.4. Aminoglycosides
Aminoglycosides are very potent antibiotics; however, their use is associated with significant 
renal and auditory toxicities. They have been successful in treating ESBL-UTIs as a mono-
therapy or in combinations with other agents. Combinations with other agents were effective 
in the treatment of CRE/CRP infections if the strain is susceptible to aminoglycosides [69].
Many of the plasmids that carry ESBL-producing genes also carry genes encodes resistant 
to aminoglycosides, mostly against tobramycin and gentamicin. In contrast, amikacin has 
retained high susceptibility rates, particularly against E. coli.
In a small study of UTI caused by highly resistant ESBL (also resistant to nitrofurantoin, fos-
fomycin, and quinolones and trimethoprim/sulfamethoxazole), amikacin intramuscular injec-
tions for 10 days achieved clinical success in 97.2%. Overall bacteriological success rate was 
94.1% on the 7–10 days after treatment [70].
In a review of 20 studies evaluating CRE infections therapy, combination of aminoglycosides 
and carbapenems displayed the lowest mortality rate (11.1%) [71].
2.9.2.5. Fluoroquinolones
In many parts of the world, E. coli fluoroquinolone resistance rates are >20% among patients 
with community-acquired uncomplicated UTI and 50% among patients with complicated 
infections. The rate of resistance is even higher against Klebsiella spp. up to 70% in one recent 
international surveillance study [8, 72].
The co-existing of ESBL and fluoroquinolone resistant is extremely high in some areas of 
the world, in those who uses quinolones prophylaxis and in returned travelers to theses 
endemic areas [73]. Therefore, they are in general not recommended in the setting of high 
ESBL isolates [74].
Sitafloxacin is the newest member (fourth generation) of the fluoroquinolone family of anti-
biotics which has a broad-spectrum activity including many anaerobes [75]. In a recent pro-
spective randomized controlled trial, comparing the clinical and bacteriological efficacy of 
sitafloxacin and ertapenem for non-bacteremic acute pyelonephritis caused by ESBL-EC was 
evaluated. Carbapenems were initially given to all patients, and then were randomized to one 
of the study drugs. The 2 arms were equal in the rates of clinical and microbiological cure [76].
These data suggest that fluoroquinolones may no longer be effective as first-line therapy for 
Gram-negative UTI in hospitalized patients and definitely in ESBL-producing organisms.
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2.9.2.6. Trimethoprim/sulfamethoxazole
Although treatment with trimethoprim/sulfamethoxazole was traditionally effective in treat-
ing UTIS, the evolution of resistance is a current major concern. The Infectious Diseases 
Society of America guideline recommends against using it if local bacterial resistance rate is 
≥20% [77]. Genes that encode for ESBLs are usually found on large plasmids accompanied by 
genetic determinants of resistance against multiple classes of antibiotics, such as aminogly-
cosides, sulfonamides, and fluoroquinolones. TMP-SMX is not recommended as an empiric 
treatment option of UTIs caused by resistant strains of E. coli or K. pneumoniae that reaches 
40–66% in some areas in the world [78].
2.9.2.7. Tigecycline
Tigecycline has potent activity against a vast majority of organisms including Gram-negatives, 
Gram-positives, and anaerobes. It has almost susceptibility rates of 100% against ESBL-
producing E. coli, however less potency against K. pneumoniae isolates producing. However, 
its use has concerning safety issues [11, 79]. Insufficient urinary excretion of the unchanged 
drug (15–22% of the dose) has prompted recommendations to avoid tigecycline for UTIs ther-
apy [80, 81].
In a systematic review of the literature, 14 patients received tigecycline for UTIs caused 
by MDR Gram-negative bacilli. In 12 patients, there were initial microbiological clearance. 
Eleven patients had evidence of clinical response. However, there were post-therapy growth 
of tigecycline-resistant organisms in 2 cases [81].
Few studies tried to overcome this obstacle by using higher than the recommended dose for 
highly resistant organisms (initial dose of 200 mg one time followed by 100 mg every 24 h) 
[82].
The efficacy of tigecycline is further limited by increasing in vitro resistance in CRE. Serum 
and urinary levels of tigecycline are low, and most experts discourage the use of tigecycline 
as monotherapy for bloodstream or urinary tract infections [83].
This agent has no activity against Pseudomonas, Proteus, Providencia, and Morganella.
2.9.2.8. The polymyxins
The polymyxins are antibacterial agents that are produced from different strains of Bacillus 
polymyxa. Colistin and polymyxin B are available commercially; both have similar chemical 
structures and antibacterial activity in vitro, however they differ in their pharmacokinetic 
profiles. They can cause significant nephrotoxicity (reported in 20–60%) and neurotoxicity 
[69]. However, the spreading of extensively resistant Gram-negative bacteria as well as the 
paucity of newer effective antimicrobials let to the extensive usage of these agents as a last 
resort [84]. The vast majority of ESBL-producing E. coli and K. pneumoniae are susceptible to 
these drugs.
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Currently, they are the backbone of most of the regimens used against the CRE/CRP organ-
isms. Common combination regimens include tigecycline, carbapenem, minocycline, rifampi-
cin, aminoglycosides, ampicillin/sulbactam, and piperacillin-tazobactam. Large clinical trials 
are underway to clarify the use of polymyxin different combinations [85].
Polymyxin B is administered directly as the active antibiotic, whereas colistin methanesulfo-
nate is converted in vivo to colistin. The optimal dosing of these agents is still controversial.
Higher doses of colistin were proposed for managing serious CRE/CRP associated infections.
A recent systematic review that included 22 studies (observational studies as well as random-
ized controlled trials) of polymyxin-based combination therapy in adult patients with infections 
caused by CRE/CRP was published. The primary outcome was a 30-day mortality. Mortality 
was significantly higher with polymyxin monotherapy compared with combination therapy 
of polymyxin with tigecycline, aminoglycosides or fosfomycin, of 1.57 (95% CI = 1.06−2.32). 
However, the authors caution about the low quality of the evidence [86].
The mechanism of colistin resistance can be generally classified intrinsic or acquired by a 
recently recognized plasmid-mediated resistance gene [87].
In November 2015, plasmid-borne colistin resistance gene mcr-1 was initially identified in 
animal and clinical samples from China. As of September 2016, the mcr-1 gene was detected 
in 35 countries worldwide in human sources in 22 countries [88]. This created a real lethal 
superbug.
2.9.2.9. Fosfomycin (Fosf)
This agent has gained attention, as it has activities against both Gram-positive and Gram-
negative MDR and XDR bacteria [89, 90–94]. It exhibits bactericidal activity against many 
Gram-positive and Gram-negative pathogens including many of the ESBL-producing E. coli 
and K. pneumoniae [91]. Fosf achieves very high concentrations within the urine and is there-
fore an excellent agent for cystitis, but it is not recommended for treating pyelonephritis or 
bacteremias due to inadequate concentrations in the blood. However, small studies have 
shown great results in using Fosf in complicated UTIs [95]. It is currently approved by the 
American Food and Drug Administration for the treatment of uncomplicated cystitis as a one-
time dose of 3 g. Several studies have shown clinical efficacy in the treatment of ESBL cystitis 
when the dosing is extended to 3 g every 48–72 h for 3 doses [96].
A meta-analysis that evaluated the antimicrobial activity, or the clinical effectiveness of Fosf, 
reviewed 17 studies. Out of a total of 5057 clinical isolates of Enterobacteriaceae, 4448 were 
ESBL producers. Almost 90% of the isolates were susceptible to Fosf. Eighty percent of 748 K. 
pneumoniae isolates produced ESBL and were susceptible to Fosf [94].
In a prospective study of 47 patients with UTI caused by E. coli-ESBL-producing organisms, 
the outcome was evaluated. Fosfomycin was used in 27 patients and 20 patients received 
meropenem. The clinical and microbiological success was similar in 2 groups; however, the 
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costs were significantly lower in the Fosf group (p < 0.001). Fosfomycin was used orally 3 g 
sachet every other night total of 3 doses, while meropenem was used as a dose for 14 days [95].
In a retrospective study, 60 patients were treated for MDR UTI. There were cases infected with 
Enterobacteriaceae, P. aeruginosa, and VRE. The clinical response rate was 55%. Chronic kidney 
disease was associated clinical failure (p = 0.04) [92].
For the carbapenem-producing organisms, a very few clinical data on using this agent are 
available.
In Europe, an intravenous Fosf formulation is available. In a small (in 11 ICU patients) 
European study, intravenous Fosf (2–4 g q6 h) in combination with other antibiotics was 
associated with good bacteriological and clinical outcomes in all patients with carbapenem-
resistant K. pneumoniae infections [96].
In an in vitro study, 365 isolates out of 2229 urine samples were evaluated. ESBL producers 
were detected in 65% were, 16% were carbapenem-resistant Enterobacteriaceae, almost 95% of 
the total isolates were susceptible to Fosf [97].
A recent, albeit pessimistic, data came from China. A study collected 233 clinical isolates CRE/
CRP Carbapenem Resistant Enterobacteriaceae/Carbapenem Resistant Pseudomonas at four different 
hospitals. Forty-five percent of the strains (105/233) were resistant to Fosf. Plasmid-mediated 
fosfomycin-modifying enzymes fosA, fosA2, fosA3, and fosA5 genes were identified [98].
2.9.2.10. Nitrofurantoin
Another oral antimicrobial agent that can be considered for the treatment of ESB cystitis is 
nitrofurantoin. One study showed clinical cure rates of 69% in patients with ESBL cystitis in 
which all isolates were also resistant to SMX/TMP and ciprofloxacin [99].
Nitrofurantoin should only be used for lower UTI and should be avoided in patients with a 
creatinine clearance less than 60 (few studies accepted GFR more than 40) mL/min as reduced 
renal function results in decreased active drug within the urine [100]. It is contraindicated in 
pregnancy.
2.9.2.11. Cefoperazone-sulbactam
In a larger in vitro study, against the GNBs, a total of 18,386 organisms including 13,224 
Enterobacteriaceae and 3536 Pseudomonas were collected (2013–2014) as part of the 
SENTRY Antimicrobial Surveillance Program. Cefoperazone/sulbactam inhibited 94% of 
Enterobacteriaceae [101]. There are limited clinical data on the usefulness of this agent against 
ESBL or CRE/CRP organisms in the urinary tract.
2.9.2.12. Ceftazidime-avibactam (Cef-Avb)
Ceftazidime, a third-generation cephalosporin, when combined with avibactam has potent 
activities against β-lactamase-producing Gram-negative pathogens including ESBL, AmpC 
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β-lactamases, and CRE. Currently, Cef-Avb is approved for complicated UTIs (limited 
to patients without other treatment options in the empiric and documented treatment of 
MDROs).
In an in vitro study, it was tested against collection of international urinary isolates (1797 iso-
lates were collected from 159 medical centers). All ESBL isolates as well as meropenem-non-
susceptible E. coli and K. pneumoniae isolates were susceptible to Cef-Avb [102].
In another study, 34,062 isolates of Enterobacteriaceae from patients (with mostly UTIs) were 
collected (International Network for Optimal Resistance Monitoring, surveillance from 39 
countries). Overall, 99.5% of isolates were susceptible to Cef-Avb. It was also active (99.9%) 
against molecularly confirmed ESBL-producing, plasmid-mediated AmpC-producing (100%), 
and ESBL- and AmpC-producing (100%). It lacks activity against the metallo-β-lactamase 
producers (NDM-1 enzyme) [103].
The REPRISE, an international, randomized, open-label trial, recruited 333 patients from 16 
countries worldwide. The study recruited patients mostly with complicated UTIs caused by 
ceftazidime-resistant Enterobacteriaceae or P. aeruginosa. They were randomly assigned, 165 to 
Cef-Avb and 168 to best available therapy. The overall proportions of patients with a clinical 
cure were similar in the 2 arms [104].
In another clinical study, Cef-Avb was compared to imipenem-cilastatin in hospitalized 
adults with serious complicated UTI due to Gram-negative pathogens. Patients were allowed 
to switch to oral ciprofloxacin after at least 4 days on the study drug. Patients in the Cef-Avb 
group had a better microbiological response (70% vs. 71%) [105].
The RECAPTURE study recruited 033 patients, who were randomized in 2 arms, 393 received 
Cef-Avb and 417 received doripenem, with possible oral antibiotic switch (total duration was 
10–14 days). Combined symptomatic resolution/microbiological were similar in the 2 arms 
(70.2% vs. 66.2%, respectively) [106].
In a recent study, the outcome of therapy with ceftazidime-avibactam (38 patients) was com-
pared to the outcome of therapy with colistin (99 patients) with CRE infections. Most patients 
received additional anti-CRE agents as part of their treatment. All-cause hospital mortality at 
30 days and after were 9% vs. 32%, respectively [107].
Salvage therapy: in a case series of 36 patients, mostly with life-threatening infections received 
Cef-Avb as a salvage therapy. The causative organisms were CRE (2 were CRP). In 65.8% of 
patients, other concurrent antibiotics were used. More than 70% of the patients experienced 
clinical and/or microbiological cure [108].
Resistance: in less than 2 years since its approval, resistant strains have been isolated. Cef-
Avb-resistant K. pneumoniae emerged in 3 patients after using Cef-Avb for 10–19 days [109].
2.9.2.13. Ceftolozane-tazobactam (Cef-Taz)
This agent was approved in 2015 for the treatment of complicated urinary tract infections 
(adults with limited or no other therapeutic options) [110]. There are many in vitro studies that 
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demonstrated activity against Gram-negative and Gram-positive microorganisms, including 
E. cloacae, E. coli, K. oxytoca, K. pneumoniae, Proteus mirabilis, P. aeruginosa as well as coverage of 
most ESBL-producing organisms and some anaerobes [110, 111].
Cef-Taz was tested in vitro against 3851 P. aeruginosa isolates collected from 32 U.S. hospitals. 
It was active against 97.0% of the isolates, which was better than 7 other broad spectra antibi-
otics. A total of 363 isolates were classified as extensively drug resistant; Cef-Taz was active 
against 76.9% of these isolates [112].
The ASPECT is a randomized, double-blind, double-dummy, non-inferiority trial over 25 
countries. 1083 patients enrolled, of whom 82% had pyelonephritis. Patients were randomly 
assigned to receive Cef-Taz or intravenous high-dose levofloxacin for 7 days. Overall, the 
composite cure rates were higher in the Cef-Taz group than in the levofloxacin. In a subgroup 
analysis, clinical cure was seen in 90% compared with 73% in patients with ESBL-producing 
uropathogens [113].
2.9.2.14. Ceftaroline/avibactam
Ceftaroline is a cephalosporin with broad-spectrum activity against Gram-positive and 
Gram-negative organisms. When Ceftaroline combined with avibactam, it gains activities 
against many ESBL-producing organisms in vitro. It was tested in one study against 272 ESBL 
Enterobacteriaceae strains. All isolates were inhibited by ceftaroline-avibactam at ≤4 μg/mL; 
however, it exhibited limited activity against Acinetobacter spp. and P. aeruginosa [114].
There are no clinical studies that tested the activity of this agent on UTIs caused by any 
MDROs.
2.9.2.15. Ceftriaxone + sulbactam + disodium edetate (Elores)
It is a novel molecule, which combines β-lactam plus β-lactamase inhibitor. It has shown 
activities against many resistant Gram-negative bacterial infections. There is a limited 
data on its spectrum, usage (mostly in India), and its role in urinary tract infections in 
specific.
In one study, Elores activity was compared to other comparators (including carbapenems) 
in treating various infectious syndromes. There were 2500 patients enrolled in the study, in 
which 24% of the patients had UTIs (no specifics on severity or the causative organisms). The 
clinical cure/improvement was achieved in 98%. There was no clear description on the types 
or the incidence of resistant organisms in the study [115].
2.10. ESBL and CRE urinary tract infections with pregnancy
Few studies have been conducted regarding the prevalence of ESBL-producing organisms in 
pregnant women. In Ireland, a low figure of 1.63% of pregnant patients was colonized with 
ESBL organisms (perianal). Similar rates were seen in a Norwegian study (2.9%) [116].
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Higher rates have been reported in other countries: 5.4% in Argentina and 15% in India 
[117]. In India, 47% in E. coli-related UTIs in pregnant patients were ESBL-producing E. coli 
[117–119].
Peripartum maternal transmission of ESBL organism to newborn infants was documented 
[120].
Recently, first outbreak of a CTX-M ESBL-producing E. coli in an Irish neonatal intensive care 
unit was reported. This outbreak was mediated by mother to neonate transmission [121].
Carbapenem are the drugs of choice for treating complicated UTIs and pyelonephritis due to 
ESBL pathogens in pregnancy [122]. In small studies, orally administered fosfomycin have 
been used to treat cystitis with ESBL pathogens with good success.
A case control study compared outcomes in pregnant women with ESBL-UTIs. Suboptimal 
treatment was noted in the majority of cases involving ESBL-UTIs (89%, n = 40), which was 
far more likely than what was observed for non-ESBL infections. Data support the importance 
of more aggressive treatment and follow-up of pregnant women with ESBL-UTIs to prevent 
secondary clinical pyelonephritis [123].
There are very limited data on CRE/CRP UTI in pregnancy. A case report of community-
acquired pyelonephritis caused by KPC-producing isolate was reported in Australia [124].
Authors were refrained from using colistin, because of its toxicity in pregnancy (category C). 
Tigecycline was not considered either (category D). Rather, they added cefepime, which is 
regarded as safe in pregnancy (category B) and offers potential synergistic activity with fosfo-
mycin, which is also an inhibitor of cell wall synthesis. In that study, the isolate was resistant 
to cefepime in vitro. By using 6 g/day as a continuous infusion, they estimated that levels in 
plasma of 20–30 μg/mL were maintained; moreover, cefepime achieved a very high concen-
tration in the urine. Therefore, it has been reasoned that concentrations of cefepime sufficient 
to inhibit the growth of K. pneumoniae (MIC >32 μg/mL) would be maintained in the urine 
and genitourinary tract. This approach was successful, as proven by sterile urine cultures 
(obtained weekly while the patient was on cefepime and 6 weeks after the end of therapy) and 
the absence of symptoms.
For these challenging cases, a new drug (see above), ceftazidime-avibactam, has shown great 
activities against most of the ESBL and many of the CRE/CRP organisms. This novel agent is 
safe during pregnancy. However, there are no randomized trials to show this activity, and it 
should be considered as a salvage therapy [125].
2.11. Duration of therapy
The optimal length of treatment UTI with highly resistant organisms has not been extensively 
studied. As there are many different causes of underlying abnormality, a simple recommen-
dation cannot be made. 10 to 14 days of antibiotics are usually recommended for patients 
with bacteremia, hypotension, and other signs of severe sepsis. Recent clinical trials included 
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complicated urinary tract infections with resistant organisms that have used the study drugs 
for 10–14 days [93, 105, 106].
2.12. Infection-control
A successful infection program should be able to recognize, screen, and isolate both colonized 
and infected patients. Standard and transmission-based precautions are strictly applied at 
all times. Other basic measures including hand hygiene, use of personal protective barriers, 
and aggressive environmental cleaning are very beneficial. Implementation of simple items-
bundles (multiple-drug resistant bundles MDROs) have shown to be very effective in control-
ling outbreaks.
Hospital-wide vs. high risk areas (ICU, dialysis centers) (routine vs. on outbreaks based) and 
clinical and bacteriological surveillance have been useful in early identifications and isolation 
of index cases. The use of molecular technologies including polymerase chain reaction (PCR) 
optimized the surveillance process [14].
A strict protocol including the above-mentioned interventions showed a great success in 
reducing the nosocomial spreading of the highly resistant organisms. During the interven-
tion, nosocomial CRE acquisition in acute care declined from a monthly high of 55.5 to an 
annual low of 4.8 cases per 100,000 patient-days (p < 0.001) [126].
2.13. Antimicrobial stewardship
Multidisciplinary program including physicians, pharmacists, and microbiologists that aims 
to control the usage of antimicrobial is mandatory. In one study, carbapenem use was strictly 
restricted through antimicrobial stewardship in an effort to control MDROs spreading in an 
ICU setting. The study protocol also included strict environmental cleaning and disinfec-
tion in addition to basic infection control measures. The rate of hospital acquired MDRO 
Acinetobacter decreased from 22.82 cases per 1000 patient-days to 2.68 cases per 1000 patient-
days after the protocol implementation (p < 0.001) [127].
2.14. Summary of recommended therapy
2.14.1. ESBL producing organisms
In general, carbapenems are the most reliable treatment for infections caused by ESBL-
producing bacteria. As shown above, the over usage of these agents resulted in the emergence 
of the CRE. Multiple trials have shown other effective-carbapenem sparing regimens.
We proposed the following:
A. Uncomplicated cystitis caused by ESBL producing E. coli and without any indwelling 
catheters or obstruent: fosfomycin would be effective (and approved) therapy. In cystitis 
caused by other ESBL producing organism, fosfomycin alone was associated with signifi-
cant clinical and microbiological failures.
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On the other hand, our (and others) clinical exercise with monotherapy and single dose of 
fosfomycin was also associated with high rates of relapse. We also have great concerns about 
the rapid progression of fosfomycin resistance. This will require further research.
Meanwhile, we are proposing fosfomycin 3 g oral sachets twice a week for 3–4 doses with 
nitrofurantoin 100 mg twice a day for 10 days (if susceptible).
B. For complicated UTIs: monotherapy with carbapenems, piperacillin-tazobactam, amino-
glycosides or ceftazidime-avibactam would be effective.
2.14.2. CRE/CRP producing organisms
Treatment of carbapenem-resistant organisms is a real challenge because of limited choices 
for effective reliable regimens. There are no randomized controlled trials evaluating differ-
ent antibiotic options for carbapenemase producers. There are many observational stud-
ies; combination therapy appears to be superior to single-drug therapy. Combinations of a 
polymyxin, tigecycline, and meropenem have met with the greatest success. Meropenem has 
been used in these combinations despite a lack of in vitro susceptibility. Recently ceftazidime-
avibactam is showing promising results. It has good activity against (nearly) all class A and 
class C β-lactamases as well as OXA-48 carbapenemases. However, it lacks activity against 
the metallo enzymes.
If we can summarize the data above:
2.15. For complicated UTIs/critically ill patients
1. Aminoglycosides (amikacin or gentamicin) or colistin.
Plus: a carbapenem or
2. Ceftazidime-avibactam (single agent).
3. Tigecycline plus colistin or aminoglycosides: have been tried in few trials.
4. Triple combinations including aminoglycoside, carbapenem, colistin, rifampicin, tigecy-
cline, and fosfomycin have demonstrated synergistic or bactericidal effects in few small 
studies.
Even with the above-mentioned regimens, failure of therapy is very common, as tigecycline 
and polymyxin do not have good clearance in the urine.
3. Conclusion
The rapid and global spread of antimicrobial-resistant organisms in recent years is a global 
challenge. The overuse of antimicrobial use in humans and animals coupled with increased 
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global connectivity facilitated the transmission of Gram-negative infections harboring 
extended-spectrum β-lactamases. When treating these infections, clinicians have a few effec-
tive antimicrobials to choose from and many are associated with significant adverse effects. 
Definitive therapy should always be guided by susceptibility testing. Expert consultation 
with an infectious disease specialist is recommended.
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